최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기약학회지 = Yakhak hoeji, v.54 no.1, 2010년, pp.1 - 7
박현정 (덕성여자대학교 약학대학) , 이상협 (덕성여자대학교 약학대학)
Valerian (Valeriana officinalis L.) is a perennial that has been used for medicinal purposes from the ancient times and valerian preparations including root and rhizome extracts are known to possess a variety of biological activities such as anticonvulsant, antidepressant, sleep aid, tranquilizer, a...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
Valerian가 주로 발견되는 지역은? | , in broad sense)은 마타리과에 속하는 다년생 식물로서 높이는 1~2미터 정도이며 짙은 청색의 잎이 있으며 흰색 또는 핑크색의 꽃을 피운다. 주로 유럽과 북아시아 지역에서 발견되지만 그 외 고위도 지역에서도 많이 발견된다. 이 식물은 이미 고래로부터 약초로 사용되어 왔고 서양쥐오줌풀의 이름인 Valerian은 라틴어 어원 Valera(strong, healthy and/or strong order의 의미)에서 유래하였으며 추출물의 경우 심한 냄새가 나는 것으로 알려져 있다. | |
Valerian란? | Valerian(서양쥐오줌풀, Valeriana officinalis L., in broad sense)은 마타리과에 속하는 다년생 식물로서 높이는 1~2미터 정도이며 짙은 청색의 잎이 있으며 흰색 또는 핑크색의 꽃을 피운다. 주로 유럽과 북아시아 지역에서 발견되지만 그 외 고위도 지역에서도 많이 발견된다. | |
이소발레르아미드의 효과는? | 이러한 점에서 valerian 추출물의 주성분인 valepotriates 및 terpenoid-isovalerates는 이소발레린산이나 이소발레르아미드의 화학적 전구체 또는 prodrug으로 인식되고 있다.15) 더욱 흥미롭게는 이소발레린산의 아미드 유도체가 바로 이소발레르아미드인데 이 화합물은 많은 정신신경계, 특히 항경련 효과가 있는 것으로 알려져 있다. |
Polydeonny, L. V., Juravleev, U. P. and Hlapseev, H. J. : Medicinal and aromatic plants of the USSR, their use, cultivation & processing. Kolos Press, Moscow, USSR, p. 360 (1979).
Hobbs, C. : Valerian, a literature review. HerbalGram 21, 19 (1989).
Bos, R. : Analytical and phytochemical studies on valerian and valerian based preparations. Offsetdrukkerij Ridderprint B. V., Ridderkerk, Groningen (1997).
Murakami, N., Ye, Y., Kawanishi, M., Aoki, S., Kudo, N., Yoshida, M., Nakayama, E. E., Shioda, T. and Kobayashi, M. : New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg. Med. Chem. Lett. 12, 2807 (2002).
Francis, A. J. P. and Dempster, R. J. W. : Effect of valerian, Valeriana edulis, on sleep difficulties in children with intellectual deficits: Randomized trial. Phytomedicine 9, 273 (2002).
Houghton, P. J. : The scientific basis for the reputed activity of valerian. J. Pharm. Pharmacol. 51, 505 (1999).
Andreatini, R., Sartori, V. A., Seabra, M. L. and Leite, J. R. : Effect of valepotriates (valerian extract) in generalized anxiety disorder: A randomized placebo-controlled pilot study. Phytother. Res. 16, 650 (2002).
Miyasaka, L. S., Atallah A. N. and Soares, B. G. : Valerian for anxiety disorders. Cochrane Database Syst. Rev. 4. Art. No. CD004515 (2006).
Hattesohl, M., Feistel, B., Sievers, H., Lehnfeld, R., Hegger, M. and Winterhoff, H. : Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine 15, 2 (2008).
Circosta, C., De-Pasquale, R., Samperi, S., Pinoand, A. and Occhiuto, F. : Biological and analytical characterization of two extracts from Valeriana officinalis. J. Ethnopharmacol. 112, 361 (2007).
Ruggero, G. F., Varsi, M. and Smith, M. C. : Antiepileptic Drugs 4th ed., Raven Press, New York, p. 581 (1995).
Nogrady, T. : Medicinal Chemistry: A biochemical approach 2nd ed., Oxford University Press, p. 225 (1988).
Fonnum, F. and Morselli, P. L. : Psychopharmacology: The third generation of progress, Raven press, New York, p. 173 and 183 (1987).
Letchamo, W., Ward, W., Heard, B. and Heard, D. : Essential oil of Valeriana officinalis L. cultivars and their antimicrobial activity as influenced by harvesting time under commercial organic cultivation. J. Agric. Food Chem. 52, 3915 (2004).
Eadie, M. J. : Could valerian have been the first anticonvulsant? Epilepsia 45, 1338 (2004).
Hassan, E., Tayebeh, R., Samaneh, E. T., Vahid, N. and Vali-OAllah, M. : Evaluation of some Iranian wild species from valerianaceae as commercial sources of valepotriates. J. Boil. Sci. 8, 549 (2008).
Kumar, V. : Potential medicinal plants for CNS disorders: an overview. Phytother. Res. 20, 1023 (2006).
Upton, R., Petrone, C., Swisher, D., Goldberg, A., McGuffin, M. and Pizzorno, N. D. : Valerian root, Valeriana officinalis, analytical, quality control and therapeutic monograph. American Herbal Pharmacopoeia (AHP) and Therapeutic Compendium (1999).
Balandrin, M. F., Van Wagenen, B. C. and Cordell, G. A. : Valerian-derived sedative agents. II. Degradation of Valmanederived valepotriates in ammoniated hydroalcoholic tincutes. J. Toxicol.-Toxin Rev. 14, 165 (1995).
Buckova, A., Grznar, K., Haladova, M. and Eisenreichova, E. : Active sbustances in Valeriana officinalis L. Cesk. Farm. 26, 308 (1977).
Bos, R., Woerdenbag, H. J., Hendriks, H., Zwaving, J. H., De Smet, P. A. G. M., Tittel, G., Wikstrm, H. V. and Scheffer, J. J. C. : Analytical aspects of phytotherapeutic valerian preparations. Phytochem. Anal. 7, 143 (1996).
Fuzzati, N., Wolfender, J. L., Hostettmann, K., Msonthi, J. D., Mavi, S. and Molleyres, L. P. : Isolation of antifungal valepotriates from Valeriana capense and the search for valepotriates in crude Valerianaceae extracts. Phytochem. Anal. 7, 76 (1996).
Balandrin, M. F. and Van Wagenen, B. C. : Use of isovaleramide as a mild anxiolytic and mild sedative agent. WO 94-28888 (1994).
Heybroek, M., Rule, G., Wells, D. S., Pesyan, A. and McCaffrey, J. : Identification and Quantitation of Isovaleramide Metabolites in Human Urine. American Association of Pharmaceutical Sciences, San Antonio, TX (2006).
Teychenne, P. F., Walters, I., Claveria, L. E., Calne, D. B., Price, J., Macgillivary, B. B. and Gompertz, D. : The encephalopathic action of five-carbon-atom fatty acids in the rabbit. Clin. Sci. Molec. Med. 50, 463 (1976).
Isoherranen, N., Yagen, B. and Bialer, M. : New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr. Opin. Neurol. 16, 203 (2003).
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P. and Perucca, E. : Progress report on new anticonvulsant drugs: a summary of the Fifth Eilat Conference. Epilepsy. Res. 43, 11 (2001).
Artman, L. D. and Balandrin, M. F. : Treatment of spasticity, convulsions by isovaleric acid derivatives CNS depressants. WO 98-08498 (1998).
Artman, L. D. : Migrain treatments including isovaleramide compounds and serotonin agonists. US patent Appl. US 0101655 A1 (2005).
Artman, L. D. and Balandrin, M. F. : Composition comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID. WO 99-446238 (1999).
Artman, L. D., Balandrin, M. F. and Smith, R. L. : Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound. WO 00- 51586 (2000).
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E. and Tomson, T. : Progress report on new anticonvulsant drugs: a summary of the Fifth Eilat Conference on new epileptic drugs. Epilepsy Res. 61, 1 (2004).
Rogawski, M. A. : Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 69, 273 (2006).
Abdelhameed, M. H., Balan, G., Hunter, J., Teitelbaum, P. and Wells, D. : Pharmacokinetics (PK) of NPS 1776 in normal healthy subjects. Annu. Meet. Am. Assoc. Pharm. Sci. Abst. 2039 (2000).
Abdelhameed, M. H., Balan, G., Hunter, J., Teitelbaum, P. and Wells, D. : Pharmacokinetics (PK) of NPS 1776 after multiple oral doses in normal healthy subjects. Annu. Meet. Am. Assoc. Pharm. Sci. Abst. 460 (2001).
Perucca, E. : Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs 16, 695 (2002).
Bialer, M. and Yagen, B. : Valproic acid: second generation. Neurotherapeutics 4, 130 (2007).
Loscher, W. : Basic pharmacology of valproate. A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16, 669 (2002).
Peterson, G. M. and Maunton, M. : Valproate: a simple chemical with so much to offer. J. Clin. Pharm. Ther. 30, 417 (2005).
Bialer, M. : Clinical pharmacology of valpromide. Clin. Pharmacokinet. 20, 114 (1991).
Payen, C., Frantz, P., Martin, O., Parant, F., Moulsma, M., Place, C. and Descotes, J. : Delayed toxicity following acute ingestion of valpromide. Hum. Exp. Toxicol. 23, 145 (2004).
Isoherranen, N., Woodhead, J. H., White, H. S. and Bailer, M. : Anticonvulsant profile of valrocemide (TV 1901): a new antiepileptic drug. Epilepsia 42, 831 (2001).
Winkler, I., Blotnik, S., Shimshoni, J., Yagen, B., Devor, M. and Bailer, M. : Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol. 146, 198 (2005).
Barel, S., Yagen, B., Schurig, V., Soback, S., Pisani, F., Peruca, E. and Bailer, M. : Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and epileptic patients. Clin. Pharmcol. Ther. 61, 442 (1997).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.